Open AccessWeekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study
Author(s) -
Shanshan Qin,
Hui Yu,
Xianghua Wu,
Zhiguo Luo,
Huijie Wang,
Si Sun,
Mingzhu Huang,
Jia Jin,
Zhonghua Tao,
Jie Qiao,
Feng Yu,
Jialei Wang,
Jianhua Chang
Publication year - 2019
Publication title -
chinese journal of cancer research/chinese journal of cancer research
Language(s) - English
Resource type - Journals
eISSN - 1993-0631
pISSN - 1000-9604
DOI - 10.21147/j.issn.1000-9604.2019.02.08
Subject(s) - gemcitabine , medicine , cisplatin , lung cancer , paclitaxel , clinical endpoint , gastroenterology , chemotherapy , oncology , clinical trial
The aim of this trial was to compare both the efficacy and the safety of a weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus cisplatin vs. gemcitabine plus cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).